회사 개요
BioHarvest Sciences Inc. operates as a biotechnology entity headquartered in Israel with significant operations in the United States, focusing on the development of a proprietary botanical synthesis platform technology designed to cultivate plant cells containing elevated concentrations of active ingredients. The company is classified within the Consumer Defensive sector and specifically within the Packaged Foods industry, a classification that typically suggests a focus on essential goods with relatively stable demand patterns, although the specific operational nature leans heavily toward nutraceuticals and pharmaceuticals. The firm currently maintains a market capitalization of $97.02 million and employs a workforce of 89 individuals, while reporting a trailing twelve-month revenue of $34.51 million. These valuation and revenue figures indicate that the company occupies a small-cap position within its industry, suggesting a limited scale of operations compared to large-cap peers and a capitalization structure that reflects early-stage growth or a niche market presence rather than broad-scale commercial dominance.
재무 건전성
BioHarvest Sciences Inc. reported a revenue of $34.51 million over the trailing twelve months, yet this gross revenue is offset by a net loss of $11,135,000 and an EBITDA of $-5,111,000, revealing a cost structure where operating expenses significantly exceed earnings before interest, taxes, depreciation, and amortization. The company generated a free cash flow of $-10,782,250, which indicates a negative cash flow situation that limits current financial flexibility and suggests that capital expenditures or working capital requirements are consuming more cash than operations generate. Margins further illustrate the financial pressure, with a gross margin of 59.3% demonstrating efficient production costs relative to sales, contrasted sharply by an operating margin of -12.4% and a profit margin of -32.3% that highlight substantial non-operating or structural costs eroding profitability. In terms of solvency, the company holds $23.04 million in cash against $14.10 million in debt, resulting in a debt-to-equity ratio of 55.42, which implies a leveraged balance sheet where equity capital is relatively low compared to debt obligations. Despite the leverage, the current ratio stands at 3.97, indicating a robust short-term liquidity position where current assets are nearly four times greater than current liabilities. Additionally, the return on equity is -83.2% and the return on assets is -9.6%, metrics that reveal management's current inability to generate positive returns on shareholder equity or the asset base, reflecting the losses incurred during this reporting period.
밸류에이션 평가
The valuation metrics present a mixed picture, with a trailing P/E ratio of N/A and a forward P/E of -107.00, implying that the market is pricing the stock based on future expectations rather than current profitability, and the negative forward P/E suggests earnings are not expected to turn positive in the near term. The price-to-book ratio is 3.81, which indicates that the market values the company at a significant premium of roughly 281% over its book value, a valuation multiple often seen in growth-oriented biotechnology firms despite current losses. Alternative valuation metrics such as a price-to-sales ratio of 2.81 and an EV/EBITDA of -17.23 further suggest that investors are valuing the company primarily on revenue generation and potential technology value rather than current cash flow or earnings power. Regarding trading range, the stock has a 52-week high of $12.80 and a 52-week low of $4.10, meaning the current price sits somewhere within this volatile band, reflecting the uncertainty associated with the company's financial trajectory. The beta value of 1.40 indicates that the stock exhibits higher volatility than the broader market, moving approximately 40% more than the benchmark index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year stands at 24.6%, demonstrating a strong top-line expansion, while earnings growth is N/A due to the company's continued net losses, implying that the expansion in revenue has not yet translated into profitability and that earnings are growing slower than revenue or are negative. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings are theoretically retained within the company, although the current losses preclude any dividend distribution. Consequently, the company reinvests its operational focus entirely into growth initiatives, research, and development rather than returning capital to shareholders through dividend payments. The overall growth and income profile is characterized by strong top-line expansion coupled with significant losses and no dividend income, positioning the equity as a pure growth vehicle with high risk and no current yield.